Rafi Mohammad A, Rao Han Zhi, Luzi Paola, Wenger David A
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Department of Neurology, Sidney Kimmel College of Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Mol Ther. 2015 Nov;23(11):1681-1690. doi: 10.1038/mt.2015.145. Epub 2015 Sep 2.
Krabbe disease is an autosomal recessive disorder resulting from defects in the lysosomal enzyme galactocerebrosidase (GALC). GALC deficiency leads to severe neurological features. The only treatment for presymptomatic infantile patients and later-onset patients is hematopoietic stem cell transplantation (HSCT). This treatment is less than ideal with most patients eventually developing problems with gait and expressive language. Several naturally occurring animal models are available, including twitcher (twi) mice, which have been used for many treatment trials. Previous studies demonstrated that multiple injections of AAVrh10-GALC into the central nervous system (CNS) of neonatal twi mice resulted in significant improvements. Recently we showed that one i.v. injection of AAVrh10-GALC on PND10 resulted in normal GALC activity in the CNS and high activity in the peripheral nervous system (PNS). In the present study, a single i.v. injection of AAVrh10-GALC was given 1 day after bone marrow transplantation (BMT) on PND10. The mice show greatly extended lifespan and normal behavior with improved CNS and PNS findings. Since HSCT is the standard of care in human patients, adding this single i.v. injection of viral vector may greatly improve the treatment outcome.
克拉伯病是一种常染色体隐性疾病,由溶酶体酶半乳糖脑苷脂酶(GALC)缺陷引起。GALC缺乏会导致严重的神经功能特征。对于症状前婴儿患者和迟发性患者,唯一的治疗方法是造血干细胞移植(HSCT)。这种治疗并不理想,大多数患者最终会出现步态和表达性语言问题。有几种天然存在的动物模型,包括抽搐(twi)小鼠,已被用于许多治疗试验。先前的研究表明,向新生twi小鼠的中枢神经系统(CNS)多次注射AAVrh10-GALC可带来显著改善。最近我们发现,在出生后第10天(PND10)静脉注射一次AAVrh10-GALC可使CNS中的GALC活性正常化,并使外周神经系统(PNS)中的活性升高。在本研究中,在PND10进行骨髓移植(BMT)后1天静脉注射一次AAVrh10-GALC。这些小鼠的寿命大大延长,行为正常,CNS和PNS的表现有所改善。由于HSCT是人类患者的标准治疗方法,添加这种单次静脉注射病毒载体可能会大大改善治疗效果。